Metropolitan Social Environments and Pre-HAART/HAART Era Changes in Mortality Rates (per 10,000 Adult Residents) among Injection Drug Users Living with AIDS

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Friedman, Samuel R ^a   West, Brooke S ^a   Pouget, Enrique R ^a   Hall, H Irene ^b   Cantrell, Jennifer ^c   Tempalski, Barbara ^a   Chatterjee, Sudip ^d   Hu, Xiaohong ^b   Cooper, Hannah L F ^e   Galea, Sandro ^f   Des Jarlais, Don C ^a,g  

^a NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Legacy Foundation   (United States)

^d Independent Consultant   (India)

^e EMORY UNIVERSITY   (United States)

^f Och Spine at New York Presbyterian Hospitals   (United States)

^g BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; COHORT ANALYSIS; DRUG ABUSE; DRUG DEPENDENCE TREATMENT; ETHNICITY; HEALTH CARE COST; HEALTH INSURANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCOME; MORTALITY; OUTCOME ASSESSMENT; PATIENT COUNSELING; RACE DIFFERENCE; SOCIAL ENVIRONMENT; TREND STUDY; URBAN AREA;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DRUG USERS; FEMALE; HUMANS; INCOME; MALE; MIDDLE AGED; PREVALENCE; REGRESSION ANALYSIS; SOCIAL ENVIRONMENT; SOCIOECONOMIC FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; SURVIVAL RATE; UNITED STATES; URBAN POPULATION;

EID: 84874342441     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057201     Document Type: Article

References (79)

1. Montaner JSG, Wood E, Kerr T, Lima V, Barrios R, et al. (2010) Expanded Highly Active Antiretroviral Therapy Coverage Among HIV-Positive Drug Users to Improve Individual and Public Health Outcomes. JAIDS Journal of Acquired Immune Deficiency Syndromes 55: S5-S9.
2. Krüsi A, Wood E, Montaner J, Kerr T, (2010) Social and structural determinants of HAART access and adherence among injection drug users. The International Journal on Drug Policy 21: 4-9.
3. Rhodes T, (2009) Risk Environments and drug harms: A social science for harm reduction approach. Int J Drug Policy 20: 193-201.
4. Friedman SR, Rossi D, (2011) A reply to Bongmba, Floyd, Palmer and Susser: An invitation to dialectics. Dialectical Anthropolgy 35: 453-457.
5. Friedman SR, Rossi D, (2011) Dialectical theory and the study of HIV/AIDS and other epidemics. Dialectical Anthropolgy 35: 403-427.
6. Krieger N, (2001) Theories for social epidemiology in the 21st century: an ecosocial perspective. Int J Epidemiol 30: 668-677.
7. Gardner E, McClean M, Steiner J, del Rio C, Burnam W, (2011) The Spectrum of Engagement in HIV Care and its Relevance to Test-and-Treat Strategies for Prevention of HIV Infection. Clin Infect Dis 52: 793-800.
8. Friedman SR, Cooper HLF, Tempalski B, Keem M, Friedman R, et al. (2006) Relationships of deterrence and law enforcement to drug-related harms among drug injectors in US metropolitan areas. AIDS 20: 93-99.
9. Friedman SR, Tempalski B, Cooper H, Lieb S, Brady J, et al. (2008) Metropolitan area characteristics, injection drug use and HIV among injectors. In: D. Richardson YT, and I Cheung, editor. Geography and Drug Addiction. Berlin: Springer-Verlag.
10. Roberts ET, Friedman SR, Brady JE, Pouget ER, Tempalski B, et al. (2010) Environmental conditions, political economy, and rates of injection drug use in large US metropolitan areas 1992-2002. Drug Alcohol Depend 106: 142-153.
11. Friedman SR, Perlis TE, Lynch J, Des Jarlais DC, (2001) Economic inequality, poverty, and laws against syringe access as predictors of metropolitan area rates of drug injection and HIV infection. Global Research Network Meeting on HIV Prevention in Drug-Using Populations pp. 147-149.
12. Cooper H, Friedman SR, Tempalski B, Friedman R, (2007) Residential segregation and the prevalence of injection drug use among Black adult residents of US metropolitan areas. American Journal of Public Health 96: 344-352.
13. Friedman SR, Pouget ER, Chatterjee S, Cleland CM, Tempalski B, et al. (2011) Drug arrests and injection drug deterrence. Am J Public Health 101: 344-349.
14. Meditz A, MaWhinney S, Allshouse A, Feser W, Markowitz M, et al. (2011) Sex, Race, and Geographic Region Influence Clinical Outcomes Following Primary HIV-1 Infection. J Infect Dis 203: 442-451.
15. Harrison K, Song R, Zhang X, (2010) Life Expectancy After HIV Diagnosis Based on National HIV Surveillance Data from 25 States, United States. J Acquir Immune Defic Syndr 53: 124-130.
16. Rubin MS, Colen CG, Link BG, (2010) Examination of Inequalities in HIV/AIDS Mortality in the United States From a Fundamental Cause Perspective. American Journal of Public Health 100: 1053-1059.
17. Lucas GM, Mullen BA, Weidle PJ, Hader S, McCaul ME, et al. (2006) Directly Administered Antiretroviral Therapy in Methadone Clinics Is Associated with Improved HIV Treatment Outcomes, Compared with Outcomes among Concurrent Comparison Groups. Clinical Infectious Diseases 42: 1628-1635.
18. Office of Management and Budget (2000) Standards for defining metropolitan and micropolitan statistical areas. Federal Register 65: 8228-82238.
19. Friedman SR, Tempalski B, Cooper H, Perlis T, Keem M, et al. (2004) Estimating numbers of injecting drug users in metropolitan areas for structural analyses of community vulnerability and for assessing relative degrees of service provision for injecting drug users. J Urban Health 81: 377-400.
20. Crum N, Riffenburgh R, Wegner S, Agan B, Tasker S, et al. (2006) Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 41: 194-200.
21. Brown B, Beschner G (1993) Handbook on Risk of AIDS: Injection Drug Users and Sexual Partners; Consortium NAR, editor. Westport, CT: Greenwood Press.
22. Springer KW, Sterk CE, Jones TS, Friedman L, (1999) Syringe disposal options for injection drug users: a community-based perspective. Subst Use Misuse 34: 1917-1934.
23. Brady JE, Friedman SR, Cooper HL, Flom PL, Tempalski B, et al. (2008) Estimating the prevalence of injection drug users in the U.S. and in large U.S. metropolitan areas from 1992 to 2002. Journal of Urban Health 85: 323-351.
24. Schneider M, Gange S, Williams C, Anastos K, Greenblat tR, et al. (2005) Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS 19: 2009-2018.
25. The Antiretroviral Theraphy Cohort Collaboration (2010) Causes of Death in HIV-1- Infected Patients Treated with Antiretroviral Therapy, 1996-2006: Collaborative Analysis of 13 HIV Cohort Studies. Clin Infect Dis 50: 1387-1396.
26. Cooper R, Kennelly J, Durazo-Arvizu R, Oh H, Kaplan G, et al. (2001) Relationship between premature mortality and socioeconomic factors in black and white populations of US metropolitan areas. Public Health Reports 116: 464-473.
27. Song R, Hall HI, Harrison KM, Sharpe TT, Lin LS, et al. (2011) Identifying the impact of social determinants of health on disease rates using correlation analysis of area-based summary information. Public Health Rep 126 Suppl 3: 70-80.
28. Kondo N, Sembajwe G, Kawachi I, van Dam R, Subramanian S, et al. (2009) Income Inequality, mortality, and self rated health: meta-analysis of multilevel studies. BMJ 10.
29. Syme S, (2005) Historical Perspective: The social determinants of disease- some roots of the movement. Epidemiol Perspect Innov 2.
30. Uhlmann S, Milloy M, Kerr T, Zhang R, Guillemi S, et al. (2010) Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction 105: 907-913.
31. Roux P, Carrieri M, Villes V, Dellamonica P, Poizot-Martin I, et al. (2008) The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Addiction 103: 1828-1836.
32. Friedman SR, Perlis T, Des Jarlais DC, (2001) Laws prohibiting over-the-counter syringe sales to injection drug users: Relations to population density, HIV prevalence, and HIV incidence. American Journal of Public Health 91: 791-793.
33. Friedman SR, Tempalski B, Brady J, Friedman JJ, Cooper H, et al. (2007) Predictors of the degree of drug treatment coverage for injection drug users in 94 metropolitan areas in the United States. International Journal of Drug Policy 18: 475-485.
34. Akaike H, (1974) A new look at the statistical model identification. IEEE Transactions on Automatic Control 19: 716-723.
35. Beal D (2005) SAS Code to Select the Best Multiple Linear Regression Model for Multivariate Data Using Information Criteria.
36. Burnham K, Anderson D, (2004) Multimodal Inference: Understanding AIC and BIC in Model Selection. Sociological Methods and Research 33: 261-304.
37. Kuha J, (2004) AIC and BIC: Comparisons of Assumptions and Performance. Sociological Methods and Research 33: 188-229.
38. SAS Institute Inc. (2002-2009) SAS 9.2. Cary, NC: SAS Institute Inc.
39. Backlund E, Rowe G, Lynch J, Wolfson M, Kaplan G, et al. (2007) Income Inequality and Mortality: A multilevel prospective study of 521,248 individuals in 50 US states. Int J Epidemiology 36: 590-596.
40. Lynch JW, Smith GD, Harper S, Hillemeier M, Ross N, et al. (2004) Income inequality a determinant of population health? Part 1. A systemic review. Milbank Quarterly 82: 5-99.
41. Marmot M, Wilkinson R (2005) Social Determinants of Health. New York: Oxford University Press.
42. Marmot M (2004) The Status Syndrome: How Social Standing Affects our Health and Longevity. New York: Times Books.
43. Wilkinson R (1999) Putting it all Together. In: Marmot M, Wilkinson R, editors. Social Determinants of Health. Oxford: Oxford University Press. pp. 256-274.
44. Link BG, Phelan J (2005) Fundamental Sources of Health Inequities. In: Mechanic D, Rogut L, Colby D, Knickman J, editors. Policy Challenges in Modern Health Care. New Brunswick: Rutgers University Press. pp. 71-84.
45. Nandi A, Galea S, Ahern J, Bucciarelli A, Vlahov D, et al. (2006) What explains the association between neighborhood-level income inequality and the risk of fatal overdose in New York City? Social Science and Medicine 63: 662-674.
46. Subramanian SV, Kawachi I, (2004) Income Inequality and Health: What Have We Learned So Far? Epidemiologic Reviews 26: 78-91.
47. Tempalski B, Cleland CM, Pouget ER, Chatterjee S, Friedman SR, (2010) Persistence of low drug treatment coverage for injection drug users in large US metropolitan areas. Subst Abuse Treat Prev Policy 5: 23.
48. Milloy M, Kerr T, Buxton J, Rhodes T, Guillemi S, et al. (2011) Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis 203: 1215-1221.
49. Kerr T, Marshall A, Walsh J, Pelepu A, Tyndall M, et al. (2005) Determinants of highly active antiretroviral therapy discontinuation among injection drug users. AIDS Care 17: 539-549.
50. Small W, Kerr T, Betteridge G, Wood E, Montaner J, (2009) Adherence to HIV Treatment among HIV-Positive Injection Drug Users within Correctional Environments in British Columbia. AIDS Care 21: 708-714.
51. Bluthenthal RN, Kral AH, Erringer EA, Edlin BR, (1999) Drug Paraphernalia Laws and Injection-Related Infectious Disease Risk Among Drug Injectors. Drug Issues 22: 1-16.
52. Bluthenthal RN, Kral AH, Lorvick J, Watters JK, (1997) Impact of law enforcement on syringe exchange programs: a look at Oakland and San Francisco. Medical Anthropology 18: 61-83.
53. Bluthenthal RN, Lorvick J, Kral AH, Erringer EA, Kahn JG, (1999) Collateral damage in the war on drugs: HIV risk behaviors among injection drug users. International Journal of Drug Policy 10: 25-38.
54. Cooper H, Moore L, Gruskin S, Krieger N, (2005) The Impact of a Police Drug Crackdown on Drug Injectors' Ability to Practice Harm Reduction: A Qualitative Study. Social Science & Medicine 61: 673-684.
55. Khan MR, Miller WC, Schoenbach VJ, Weir SS, Kaufman JS, et al. (2008) Timing and duration of incarceration and high-risk sexual partnerships among African Americans in North Carolina. Annals of Epidemiology 18: 403-410.
56. Aitken C, Moore D, Higgs D, Kelsall J, Kerger M, (2002) The impact of a police crackdown on a street drug scene: evidence from the street. The International Journal of Drug Policy 13: 189-198.
57. Thomas JC, Sampson LA, (2005) High rates of incarceration as a social force associated with community rates of sexually transmitted infection. The Journal of Infectious Diseases 191: S55-S60.
58. Small W, Rhodes T, Woods E, Kerr T, (2007) Public injection settings in Vancouver: physical environment, social context and risk. Int J Drug Policy 18: 27-36.
59. Wood E, Spittal PM, Small W, et al. (2004) Displacement of Canada's largest public illicit drug marker in responds to a police crackdown. Canada Medical Association Journal 170: 1551-1556.
60. Galea S, Tracy M, Hoggatt K, Dimaggio C, Karpati A, (2011) Estimated deaths attributable to social factors in the United States. American Journal of Public Health 101: 1456-1465.
61. Galea S, Ahern J, Rudenstine S, Wallace A, Vlahov D, (2005) Urban built environment and depression: a multilevel analysis. J Epidemiol Community Health 59: 822-827.
62. Chaix B, Leal C, Evans D, (2010) Neighborhood-level confounding in epidemiologic studies: unavoidable challenges, uncertain solutions. Epidemiology 21: 124-127.
63. CDC (2011) Vital Signs: HIV Prevention Through Care and Treatment. MMWR 60: 1618-1623.
64. Cooper HL, Bossak BH, Tempalski B, Friedman SR, Des Jarlais DC, (2009) Temporal trends in spatial access to pharmacies that sell over-the-counter syringes in New York City health districts: relationship to local racial/ethnic composition and need. J Urban Health 86: 929-945.
65. Harper S (2005) Estimates of GINI Coefficients based on US Census Bureau Data. Ann Arbor, MI: University of Michigan, School of Public Health, Center for Social Epidemiology and Population Health.
66. US Census Bureau (1990) Population Estimates. In: Bureau UC, editor. Washington, DC.
67. US Census Bureau (2000) Population Estimates. In: Bureau UC, editor. Washington, DC.
68. Bureau of Labor Statistics (2009) Local area unemployment statistics. United States Department of Labor.
69. US Census Bureau (1992, 2002) Census of Goverments. United States Census Bureau.
70. US Census Bureau (1990) Housing and Household Economic Statistics Division: Poverty Index. In: Bureau UC, editor. Washington, DC.
71. US Census Bureau (2000) Housing and Household Economic Statistics Divisioj: Poverty Index. In: Bureau UC, editor. Washington, DC.
72. Cooper HLF, Friedman S, Tempalski B, Friedman R, Keem M, (2005) Racial/ethnic disparities in injection drug use in 94 U.S. metropolitan statistical areas in 1998. Annals of Epidemiology 15: 326-334.
73. Tempalski B, McQuie H, (2009) Drugscapes and the role of place and space in injection drug use-related HIV risk environments. Int J Drug Policy 20: 4-13.
74. Association of Religious Data Archives (2009) Churches and church membership in the United States, 1990 (Counties).
75. Federal Bureau of Investigations (2009) Crime in the United States.
76. Substance Abuse and Mental Health Services Administration Office of Applied Studies1992-2002 TREATMENT EPISODE DATA SET (TEDS), [Computer file]. U.S. Dept. of Health and Human Services: Prepared by Synectics, Incorporated.
77. Substance Abuse and Mental Health Services Administration (1998) National Household Survey on Drug Abuse: Main Findings 1996. SAMSHA, Office of Applied Studies, Rockville, MD.
78. Tempalski B, Lieb S, Cleland CM, Cooper H, Brady JE, et al. (2009) HIV prevalence rates among injection drug users in 96 large US metropolitan areas, 1992-2002. J Urban Health 86: 132-154.
79. Cooper HLF, Brady JE, Friedman SR, Tempalski B, Gostnell K, et al. (2008) Estimating the prevalence of injection drug use among Black and White adults in large US metropolitan areas over time (1992-2002): Estimation methods and prevalence trends. Journal of Urban Health 85: 826-856.